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Protein nativity is one of the most critical factors for the quality of antigens used
as immunogens and the reactivities of the resultant antibodies. The preparation and
purification of native viral antigens in conventional cell-based protein expression systems
are often accompanied by technical hardships. These challenges are attributable mainly
to protein aggregation and insolubility during expression and purification, as well as to
very low expression levels associated with the toxicity of some viral proteins. Here, we
describe a novel approach for the production of monoclonal antibodies (mAbs) against
nucleocapsid protein (NP) of the Middle East respiratory syndrome coronavirus (MERS-
CoV). Using a wheat germ cell-free protein synthesis system, we successfully prepared
large amounts of MERS-CoV NP antigen in a state that was highly soluble and intact for
immunization. Following mouse immunization and hybridoma generation, we selected
seven hybridoma clones that produced mAbs with exclusive reactivity against MERS-
CoV NP. Epitope mapping and subsequent bioinformatic analysis revealed that these
mAbs recognized epitopes located within relatively highly conserved regions of the
MERS-CoV amino-acid sequence. Consistently, the mAbs exhibited no obvious cross-
reactivity with NPs derived from other related viruses, including SARS coronavirus. After
determining the optimal combinations of these mAbs, we developed an enzyme-linked
immunosorbent assay and a rapid immunochromatographic antigen detection test that
can be reliably used for laboratory diagnosis of MERS-CoV. Thus, this study provides
strong evidence that the wheat germ cell-free system is useful for the production of
diagnostic mAbs against emerging pathogens.
Keywords: MERS-coronavirus, nucleocapsid, antigen, detection, diagnosis, monoclonal antibody, cell-free
protein synthesis
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INTRODUCTION
Middle East respiratory syndrome coronavirus (MERS-CoV),
a novel human coronavirus, was first isolated in 2012 in
the Arabian Peninsula (Zaki et al., 2012). MERS-CoV is a
positive-sense, enveloped, single-stranded RNA virus of genus
Betacoronavirus within subfamily Coronavirinae (de Groot et al.,
2013). MERS-CoV infection often causes fever, cough, and severe
pneumonia, occasionally accompanied by renal disease (Banik
et al., 2015). More than 1600 laboratory-confirmed cases with
high fatality rates (∼36% mortality) have been reported (World
Health Organization [WHO], 2016). Because there is currently
no specific antiviral drug or vaccine approved for clinical use
against MERS-CoV, rapid diagnostic tests are urgently required
to manage and control this virus. Indeed, rapid and specific
diagnosis is essential for preventing the spread of any kind of
infectious disease.
At present, laboratory testing for MERS-CoV is performed by
quantitative reverse transcription-PCR assay (qRT-PCR) and RT-
loop-mediated isothermal amplification (RT-LAMP) (Corman
et al., 2012a,b; Shirato et al., 2014). These tests can detect nucleic
acids derived from MERS-CoV in clinical respiratory, serum, and
stool specimens. These nucleic acid-based tests require molecular
techniques and specialized equipment, and are thus not suitable
for point-of-care testing (POCT) or bedside diagnosis. Therefore,
it is necessary to develop alternative methods that can be adapted
to rapid and reliable clinical detection of MERS-CoV antigen,
including enzyme-linked immunosorbent assay (ELISA) and
immunochromatographic test (ICT).
Middle East respiratory syndrome coronavirus comprises four
structural proteins: spike (S), envelope (E), membrane (M), and
nucleocapsid (N) (van Boheemen et al., 2012). S protein is a major
component of the viral surface that binds dipeptidyl peptidase 4
(DPP4), enabling the virus to enter and infect cells (Raj et al.,
2013). Therefore, S protein is considered to be a prospective
therapeutic and diagnostic target (Song et al., 2013; Jiang et al.,
2014; Zhang et al., 2014; Li et al., 2015). However, because
neutralizing antibodies mainly target this antigen, coronaviruses
express several mutant forms of S protein in order to escape the
immune response and achieve viral persistence (Tang et al., 2014).
On the other hand, amino-acid mutations in N protein are much
less common (Wernery et al., 2015). N protein is produced at
high levels within infected cells, and is thus a promising candidate
target for clinical diagnosis (Lau et al., 2004; He et al., 2005;
Kogaki et al., 2005; Liang et al., 2013; Chen et al., 2015).
N protein functions in packaging the viral genomic RNA to
form the helical nucleocapsid, as well as in viral transcription
and assembly (McBride et al., 2014). It has three distinct and
conserved domains: the N-terminal domain (NTD), linker region
(LKR), and C-terminal domain (CTD) (McBride et al., 2014). The
NTD of human coronavirus N protein contains highly conserved
motifs (Yu et al., 2005; Chang et al., 2014). To prevent cross-
reactivity with other human coronaviruses and specifically detect
MERS-CoV, it is necessary to develop antibodies that target
non-conserved regions. However, the viral structural protein is
generally unstable and insoluble in its monomeric or oligomeric
forms, making it difficult to prepare antigen for immunization.
Moreover, refolding of solubilized viral proteins by denaturing
agents often results in misfolding and functional loss (Schein,
1991). To overcome these problems, we recently developed a
cell-free based viral protein production system using wheat germ
extract (Matsunaga et al., 2014). Because wheat is a eukaryote, this
system can synthesize properly folded and biologically active viral
proteins equivalent to those expressed in mammalian cells (Endo
and Sawasaki, 2005, 2006; Goshima et al., 2008).
In this study, we synthesized recombinant MERS-CoV N
protein (MERS-NP) and raised monoclonal antibodies (mAbs)
that could specifically detect this protein. We also describe the
development and evaluation of a rapid test format including
ELISA and ICT that can be used in POCT for MERS-CoV
infection.
MATERIALS AND METHODS
Expression Plasmid
Complementary DNAs encoding nucleocapsid proteins
(NPs) of human coronaviruses (MERS-CoV, GenBank No.
NC_019843; SARS-CoV, GenBank No. NC_004718; HCoV-
HKU1, GenBank No. NC_006577; HCoV-OC43, GenBank
No. NC_005147; HCoV-229E, GenBank No. NC_002645;
HCoV-NL63, GenBank No. NC_005831) were synthesized
by GENEWIZ (South Plainfield, NJ, USA). Synthetic cDNAs
were digested with XhoI and KpnI and inserted into pEU-
E01-His-TEV-MCS and pcDNA3-HA-MCS. To generate the
expression vector for antigen production in the wheat germ
cell-free system, the MERS-NP open reading frame encoding
amino acids 122–413 was amplified by PCR using the forward
primer 5′-GAGAGATATCTGGGTGCATGAGGACGGAG-3′
and the reverse primer 5′-GAGAGATATCTCAGTCTGTG
TTCACATCG-3′. The amplified fragment was cloned into the
EcoRV site of vector pEU-E01-His-TEV-MCS (CellFree Sciences,
Yokohama, Japan). Deletion mutants of MERS-NP for epitope
mapping were generated using the PrimeSTAR Mutagenesis
Basal kit (Takara Bio, Otsu, Japan). The R395H mutation was
introduced into MERS-NP using the PrimeSTAR Mutagenesis
Basal kit (Takara Bio, Otsu, Japan).
Cell-free Protein Synthesis and
Purification
In vitro transcription and cell-free protein synthesis were
performed as previously described (Takai and Endo, 2010; Takai
et al., 2010; Senchi et al., 2013; Matsunaga et al., 2014, 2015). For
cell-free protein synthesis, WEPRO7240H wheat germ extract
(CellFree Sciences, Yokohama, Japan) was used in the bilayer
translation method as previously described (Matsunaga et al.,
2014). Synthesized proteins were confirmed by immunoblotting.
His-MERS-NP (122-413) protein, used for mouse
immunization, was synthesized using a Protemist XE robotic
protein synthesizer (CellFree Sciences, Yokohama, Japan). The
cell-free translation reaction mixture (6 ml) was separated into
soluble and insoluble fractions by centrifugation at 15,000 rpm
for 15 min. The soluble fraction was mixed with Ni-Sepharose
High Performance beads (GE Healthcare, Waukesha, WI, USA)
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in the presence of 20 mM imidazole. The beads were washed
three times with washing buffer [20 mM Tris-HCl (pH 7.5),
500 mM NaCl] containing 40 mM imidazole. His-MERS-NP
(122–413) was then eluted in washing buffer containing 500 mM
imidazole. Amicon Ultra centrifugal filters (Millipore, Bedford,
MA, USA) were used to concentrate purified His-MERS-NP
(122–413) by approximately 10–20-fold. Protein concentration
was determined using the Bradford method, with bovine serum
albumin (BSA) as a protein standard.
Immunization and Generation of
Hybridomas
Immunization of BALB/c mice and generation of hybridomas
producing anti-MERS-NP antibody were carried out as
previously described (Kimura et al., 1994, 1996; Matsunaga et al.,
2014). Primary antibodies in hybridoma culture supernatant were
tested by immunoblot analysis with non-tagged recombinant N
protein. Animal experiments were performed ethically according
to the Guidelines for Animal Experiments at Yokohama
City University. All of the procedures were approved by the
Committee on Experimental Animals at the Yokohama City
University.
Purification of mAbs
Hybridoma cells were grown in CD hybridoma medium AGT
medium (Thermo Fisher Scientific, Rockford, IL, USA). Primary
antibodies in the culture supernatant of each clone were
separated by centrifugation at 8,000 rpm for 15 min and
eluted with AcroSep Hyper DF columns (Pall, New York,
NY, USA). Samples were then further concentrated 10–20-
fold using Amicon Ultra centrifugal filters (Millipore, Bedford,
MA, USA). Concentrations of purified IgG were determined
by measuring the absorbance at OD280. Immunoglobulin
characterization was carried out using the IsoStrip mouse
monoclonal antibody isotyping kit (Roche Diagnostics, Basel,
Switzerland).
Homology Modeling of MERS-NP and
Epitope Localization Analysis
The dimer model of MERS-NP was constructed by homology
modeling based on the partial structure of SARS-NP (PDB
code. 1SSK, Huang et al., 2004; PDB code. 2CJR, Chen
et al., 2007) using the MODELLER9.15 software (Webb and
Sali, 2014). Protein structures not registered in PDB were
estimated by the I-TASSER and QUARK servers and used
as templates for homology modeling (Xu and Zhang, 2012;
Yang et al., 2015). Energy minimization of the generated
model was carried out using Swiss PDB viewer4.1 (Guex
and Peitsch, 1997). Surface localization of each epitope was
determined using the UCSF Chimera software (Pettersen et al.,
2004).
Immunoprecipitation Analysis
Immunoprecipitation was performed as previously described
(Miyakawa et al., 2015). Briefly, HEK293A cells were grown
on a 100-mm dish for 24 h, and then transfected with HA-
MERS-NP. Cell lysates were immunoprecipitated with EZview
Red anti-HA Affinity Gel (Sigma–Aldrich) or 2 µg of each
anti-MERS-NP antibody mixed with protein G-Sepharose (GE
Healthcare, Little Chalfont, UK). Bound proteins were analyzed
by immunoblotting.
Selection of the Optimal Pair of mAbs for
Sandwich ELISA
Each mAb was diluted in 50 mM of carbonate buffer (pH 9.6) to a
concentration of 10 µg/mL, and then added to an ELISA plate
(AGC TECHNO GLASS, Shizuoka, Japan). To immobilize the
antibodies, the plate was incubated overnight at 4◦C. Wells were
blocked with PBS containing 2% (w/v) skim milk for 1 h at room
temperature (RT). After three washes with PBS containing 0.05%
(v/v) Tween-20 (PBS-T), 100 µL of antigen protein (1 ng/mL)
diluted with PBS-T or blank (PBS-T alone) was added and
incubated for 60 min at RT. After three washes with PBS-T,
100 µL of each mAb conjugated with horseradish peroxidase
(HRP) was added into each well and incubated for 60 min
at RT. Antibody labeling was performed using the Peroxidase
Labeling Kit -NH2 (Dojindo Laboratories, Kumamoto, Japan).
After three washes with PBS-T, 100µL of ABTS substrate solution
(Kirkegaard & Perry Laboratories, Washington, DC, USA) was
added and incubated for 30 min at RT. Absorbance at 415/492 nm
was measured on a plate reader, and the signal-to-noise ratio
(S/N) was calculated.
Selection of the Optimal Antibody Pair
for ICT
For the test line, anti-MERS-NP antibodies #20, #29, and #46
were diluted in 50 mM of phosphate buffer (pH 8.0) to a
concentration of 1 mg/mL and immobilized on a nitrocellulose
membrane (Millipore, Bedford, MA, USA). To prepare the
control line, an anti-mouse IgG antibody was diluted to
0.125 mg/mL and immobilized onto another area of the same
membrane. The membrane was dried and blocked at RT, washed
with deionized water, and lyophilized.
To produce conjugate pads, anti-MERS-NP mAbs #5,
#13, and #20 were diluted in 50 mM of phosphate buffer
(pH 8.0) to a concentration of 0.05 mg/mL and labeled with
colloidal gold (Tanaka Kikinzoku Kogyo, Tokyo, Japan).
The colloidal gold-conjugated mAbs were blocked with
0.5% casein (Kanto Chemical, Tokyo, Japan). After washing
three times with phosphate buffer (pH 7.0), labeled mAbs
were diluted to an OD525 4.4 and impregnated into glass
fibers (Millipore, Bedford, MA, USA). The glass fibers were
lyophilized.
Immunochromatographic strips were generated by
assembling a glass fiber (sample pad), conjugate pad,
nitrocellulose membrane, and liquid absorbent pad. To
compare each combination of antibodies, antigen proteins were
diluted to 12.5 ng/0.1 mL in 40 mM phosphate buffer containing
150 mM NaCl and applied to the strips. The color intensity of red
lines at the test and control position and the background of the
membrane were visually observed and evaluated after a 15 min
reaction.
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Bioinformatic Analysis
Homology of NPs among human coronaviruses (MERS-
CoV, GenBank No. NC_019843; SARS-CoV, GenBank No.
NC_004718; HCoV-HKU1, GenBank No. NC_006577; HCoV-
OC43, GenBank No. NC_005147; HCoV-229E, GenBank No.
NC_002645; HCoV-NL63, GenBank No. NC_005831) was
analyzed by multiple sequence alignment using the MUSCLE
software (Edgar, 2004).
To examine amino-acid variability among NPs of each MERS-
CoV strain, 113 MERS-NP sequences from the GenBank were
aligned using the MUSCLE software. A Shannon entropy score
was calculated for each position in the protein alignment
as previously described (Yang, 2009). Phylogenetic trees were
generated via the maximum-likelihood method with 1000
bootstrap replicates using MEGA5 after removal of 100%
identical sequences (Tamura et al., 2011). The dataset was
analyzed using the Jones–Taylor–Thornton (JTT) amino-acid
substitution model.
Preparation and Quantitation of
MERS-CoV
Prototype strain of MERS-CoV were provided by Drs. Ron A.
M. Fouchier and Bart L. Haagmans (Erasmus Medical Center).
MERS-CoV were propagated in Vero cells expressing TMPRSS2,
as described previously (Shirato et al., 2013). Viral samples
were concentrated by centrifugation from culture supernatant
of MERS-CoV infected cells. MERS-CoV was inactivated by
addition of Nonidet P-40 (NP-40) to a final concentration of 1%
(v/v) prior to each immunoassay.
Viral RNA was extracted from the samples using the QIAamp
viral RNA mini kit (Qiagen, Valencia, CA, USA). Quantitation
of viral copy number was carried out by reverse-transcription
droplet digital PCR (RT-ddPCR) using One-Step RT-ddPCR
Advanced kit for Probes (Bio-Rad, Hercules, CA, USA). A 20 µL
reaction was set up containing 2 µL of RNA (equivalent to
20 ng), 2 µL of a mixture of forward/reverse primers and probe,
1 µL of 300 mM DTT, 2 µL of reverse transcriptase, 8 µL of
RNase-free water, and 5 µL of Supermix. Primers and probe
sets for Orf1a were used as previously reported in qRT-PCR
assays (Corman et al., 2012b); final concentrations of primers and
probe were 900 and 250 nM, respectively. Droplets were formed
in a QX200 droplet generator (Bio-Rad, Hercules, CA, USA).
Thermal cycling conditions were as follows: 42◦C for 60 min
for the RT reaction; 95◦C for 10 min; 40 cycles of 95◦C for
30 s and 56◦C for 1 min; and a final 10 min denaturation step
at 95◦C. After thermal cycling, plates were transferred to the
QX200 droplet reader (Bio-Rad, Hercules, CA, USA). Positive
droplets containing amplification products were discriminated
from negative droplets by applying a fluorescence amplitude
threshold in the QuantaSoft software (Bio-Rad, Hercules, CA,
USA).
Immunoblot Analysis
Cell-free synthesized proteins or cell culture supernatants
containing inactivated MERS-CoV were mixed with an equal
volume of 2X SDS sample buffer [125 mM Tris-HCl (pH
6.8), 4% SDS, 20% glycerol, 10% 2-mercaptoethanol and
0.01% bromophenol blue] and heated at 100◦C for 5 min.
After separation by 12.5% or 15% SDS-PAGE using Hi-QRAS
Gel N (Kanto Chemical, Tokyo, Japan), the proteins were
electrotransferred onto an Immobilon-P PVDF Transfer
Membrane (Millipore, Bedford, MA, USA) as described
previously (Nishi et al., 2014). The membrane was blocked in
Tris-buffered saline (TBS) containing 2% (w/v) skim milk for
30 min, and then incubated for 1 h with anti-MERS-NP mAbs
or anti-His polyclonal antibody (GTX115045; GeneTex, Irvine,
CA, USA) in TBS containing 0.1% (v/v) Tween 20 (TBS-T;
1:1000 dilution) and 0.4% (w/v) skim milk. After three washes
with TBS-T, the membrane was incubated for 60 min in PBS
containing HRP-conjugated goat-anti mouse or rabbit IgG
antibody (1:10000 dilution; GE Healthcare). After an additional
three washes in TBS-T, proteins were detected with SuperSignal
West Dura Extended Duration Substrate (Thermo Fisher
Scientific, Rockford, IL, USA) or Immobilon (Millipore, Bedford,
MA, USA) on a Lumi-Imager F1 (Roche Diagnostics, Basel,
Switzerland).
Detection Limit of Antigen-Capture
ELISA
Sensitivity analysis of antigen-capture ELISA was carried out
as described above with some modifications. Briefly, mAb
(#46) was immobilized onto a plate at a concentration of
2.5 µg/mL. After the plate was blocked, inactivated MERS-CoV
(1.2 × 106 copies/0.1 mL) and recombinant antigen protein
(1 ng/0.1 mL) were serially twofold diluted with PBS-T and
subjected to analysis. After reaction with HRP-conjugated mAb
(#20), a chromogenic reaction was conducted by adding 100 µL
of TMB Substrate solution (Kirkegaard & Perry Laboratories,
Washington, DC, USA) per well, followed by incubation for
5 min; the reaction was halted by the addition of 100 µL of
1 M H2SO4. Absorbance at 450/630 nm was measured on a plate
reader.
Detection Limit of ICT
Immunochromatographic detection of MERS-CoV was carried
out as described above with some modifications in preparation
of the conjugate pad. Conjugation of mAb #20 with colloidal gold
was performed at a concentration of 0.2 mg/mL. After blocking
and washing, conjugated pads impregnated with labeled antibody
solution at an OD525 of 8.0.
Sensitivity of ICT was evaluated by adding serially twofold
diluted inactivated MERS-CoV (1.2 × 107 copies/0.1 mL) and
recombinant antigen protein (2 ng/0.1 mL).
RESULTS
Production of mAbs to Target
Nucleocapsid Protein of MERS-CoV
Previous studies described antigenic cross-reactivity among the
NTDs of N proteins of human coronaviruses, including SARS-
CoV (Yu et al., 2005). To minimize the cross-reactivity when
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FIGURE 1 | Production of mAb using wheat germ cell-free synthesized nucleocapsid antigen. (A) Schematic representation of antigen protein production.
Recombinant Histidine (His)-tagged N-terminally truncated MERS-NP (122–413) was produced in a wheat germ cell-free system, and then purified using
nickel-chelated Sepharose beads. Each protein fraction was analyzed by SDS-PAGE and visualized by CBB staining. Red dot and arrow indicate the target protein.
NC, negative control; T, total fraction; S, supernatant; P, precipitate; FT, flow-through; E1–5, elution fractions 1–5. (B) Schematic diagram of hybridoma cells
production generating anti-MERS-NP mAb. Purified His-MERS-NP (122–413) was injected into BALB/c mice. After 4 weeks, immunized mouse splenocytes were
fused with myeloma cells, and 48 hybridoma cells were established. Of the 48 clones, seven exhibited relatively high reactivity to antigen proteins, as revealed by
immunoblotting analysis, and were selected for further investigation. (C) List of selected hybridoma clones producing mAbs.
generating mAbs, we produced N-terminally deleted MERS-NP
(amino acids 122–413) as an antigen for antibody production.
Complementary DNA encoding MERS-NP (122–413) was sub-
cloned into pEU-His, a vector designed for expression of His-
tagged proteins in the wheat germ cell-free system. As predicted,
His-tagged MERS-NP (122–413) was expressed (Figure 1A). The
protein was purified from the soluble fraction of the extracts
using Ni-Sepharose beads followed by elution with imidazole.
The purified protein was used to immunize BALB/c mice.
After 4 weeks, splenocytes were isolated and hybridomas were
generated (Figure 1B). Ultimately, 48 stable hybridomas were
obtained and designated #1–#48. Among the 48 clones, seven
(#5, #13, #20, #25, #29, #45, and #46) were selected for
further investigation based on their reactivity to MERS-NP in
immunoblot analysis (Figure 1C).
Epitope Analysis of Anti-MERS-NP mAb
We next performed epitope mapping to determine the antibody
binding sites. Using cell free-synthesized deletion mutants
of MERS-NP, we carried out immunoblot analyses with the
generated antibodies. In the first screen, we used six deletion
mutants (Mut1-6; Figures 2A,B); the results revealed that two
mAbs (#13 and #46) recognized the middle region corresponding
to LKR, whereas the remaining five mAbs (#5, #20, #25,
#29, and #45) bound the C-terminal end of the protein
(Figures 2A,B). More precise epitope mapping was performed
using five additional deletion mutants (Mut7-11; Figures 2A,B);
the results are summarized in Figure 2C.
We next investigated whether the antigenic epitopes were
located on the surface of MERS-NP. To this end, we used a
previously reported solution structure of SARS-NP (PDB ID;
1SSK, 2CJR) for homology modeling of MERS-NP (Huang et al.,
2004; Chen et al., 2007). Molecular modeling of MERS-NP
using the UCSF Chimera software revealed that all mAb binding
regions were located on the surface of N protein (Figure 3).
Immunoprecipitation Assay
Next, because an antibody suitable for immunoprecipitation
is likely to be conformation-sensitive, we examined whether
our selected antibodies could be used in immunoprecipitation
analysis (Mancia et al., 2007; Takeda et al., 2015). Cell
lysates from HEK293A cells expressing HA-tagged MERS-
NP were subjected to immunoprecipitation analysis with each
selected antibody (Figure 4). The results revealed that all of
the generated mAbs could be used for immunoprecipitation
analysis.
Screening for Appropriate Combinations
of mAbs for Antigen-Capture ELISA and
ICT
We next determined the optimal pair of mAbs for antigen-
capture ELISA by evaluating all possible combinations of
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FIGURE 2 | Epitope mapping of mAbs. (A) Schematic diagram of MERS-NP putative domain architecture and deletion mutants. For epitope mapping, 11 deletion
mutants were produced as His-tagged proteins in the wheat germ cell-free system. NTD, N-terminal domain; LKR, flexible linker region; CTD, C-terminal domain.
(B) Confirmation of protein expression. His-tagged NP and deletion mutants were immunoblotted with anti-His-tagged antibody. (C) Summary of epitope analysis.
Reactivity of each mAb to deletion mutants was evaluated by immunoblotting. + and − indicate positive and negative detection, respectively. NT; not tested.
Negative detections are highlighted in gray.
immobilized and labeled mAbs (Figure 5A). The combinations
of #46/#5, #20/#13, #29/13, #46/#45, and #46/#20 exhibited
higher S/N ratios than other pairs (Figure 5B). Based on
these data, we constructed immunochromatographic strips
using five pairs of mAbs (Figure 6A). We searched for
the combinations yielding the highest color intensity at
the positive control at the appropriate position with the
lowest overall background on the rest of the membrane. We
found that immobilization of mAb #46 and colloidal gold
conjugation of #20 was the optimal combination for ICT
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FIGURE 3 | Epitope localization in MERS-CoV-NP structural model. Positions of epitopes in a structural model of dimer-forming MERS-CoV-NP, constructed
by homology modeling using the structure of SARS-NP (PDB ID. 1SSK, 2CJR). Epitope localizations of each mAb are highlighted in different colors.
(Figures 6B,C). Thus, we selected mAbs #46 and #20 for further
investigation.
No Evidence of Cross-Reactivity of
Anti-MERS-CoV-NP Antibody to Other
Human Coronaviruses
We next investigated the specificity of our newly developed
mAbs. Multiple alignment of NPs derived from various human
coronaviruses revealed that the amino-acid sequences targeted by
the selected antibodies were specific to MERS-CoV (Figure 7A).
Consistent with these data, immunoblot analysis revealed that
our mAbs did not recognize NPs from other coronaviruses
(Figure 7B).
Reactivity of Antibodies to Divergent
Strains of MERS-CoV
To estimate the reactivity of mAbs with different strains of
MERS-CoV, we compared the amino-acid sequences of epitopes
between 113 isolated strains. Shannon entropy and phylogenetic
analysis revealed that the amino-acid sequence of MERS-NP is
highly conserved (Figures 8A,B). Notably, no obvious amino-
acid mutation was observed in the binding region of #46
(Figures 8A,C). However, the C-terminal amino acid sequence
targeted by #20 was rather variable, containing a specific
mutation (R395H) in two strains (Figures 8A,C). Therefore,
we performed site-directed mutagenesis to introduce the R395H
mutation into MERS-NP and examined the effect on the
reactivity of #20 antibody by immunoblot analysis. The results
showed that mAb #20 could still detect the R395H mutant
(Figure 8D).
Reactivity of mAbs to Virion
Nucleocapsid Protein
We next performed immunoblot analysis with virions released
into the cell-culture supernatant of MERS-CoV infected cells.
Our mAbs detected a 45 kDa protein band consistent with
the molecular mass of the MERS-NP (Figure 9A). No other
bands were detected by the mAbs, demonstrating their specificity
for MERS-NP. Thus, our newly developed antibodies could
detect NP antigen derived from MERS-CoV virions as well as
recombinant NP.
Sensitivity of Antigen-Capture ELISA
Using the optimal antibody pair (#46 and #20) identified above,
we determined the detection threshold for antigen recognition
by antigen-capture ELISA. Our results revealed that our system
was highly sensitive to recombinant antigen, capable of detecting
the protein at a concentration of 0.0625 ng/0.1 mL (Figure 9B).
In parallel, we investigated the detection limit of ELISA for
MERS-CoV virions permeabilized by addition of NP-40. The
detection limit of the system was 1.5 × 105 copies/0.1 mL
(Figure 9B).
Detection Limit of ICT for MERS-CoV
Finally, we evaluated the sensitivity of ICT for MERS-CoV. For
this purpose, serial dilutions of purified NPs were subjected to
ICT. The results revealed that ICT was highly sensitive, with a
detection limit of 0.5 ng/0.1 mL. We next examined the detection
limit for virions prepared in phosphate buffer containing 1% NP-
40. ICT could detect virions at a concentration of 3.0 × 106
copies/0.1 mL (Figure 9C).
Frontiers in Microbiology | www.frontiersin.org 7 April 2016 | Volume 7 | Article 509
fmicb-07-00509 April 18, 2016 Time: 14:12 # 8
Yamaoka et al. Development of a Diagnostic Test for MERS-CoV
FIGURE 4 | Immunoprecipitation analysis with generated mAbs.
Immunoprecipitation analysis. HEK293A cells were transfected with plasmid
vector encoding HA-tagged MERS-NP, and cell lysates were collected after
48 h. Samples were subjected to for immunoprecipitation with anti-MERS-NP
antibodies followed by immunoblotting analysis with anti-HA antibody.
DISCUSSION
We report the development and prospective evaluation of an
ELISA and ICT for the quantitative and qualitative detection
of MERS-CoV-NP antigen. Our newly developed assays provide
rapid detection of a broad range of NP antigens derived from
various isolates of MERS-CoV. Because NP is a principal
structural protein that is more abundantly expressed than other
MERS-CoV antigens, targeting NP for clinical diagnosis is both
reasonable and practical (Chen et al., 2015).
The quality of a mAb is determined mostly by the antigen
design, adjuvant selection, and antigen quality (Leenaars and
Hendriksen, 2005; Stills, 2005). In particular, preparation of
high-quality antigen is essential for creation of a specific mAb.
There are several methods for preparing immunizing virus
antigen, including synthetic peptide, virus-like particle (VLP),
and purified recombinant protein. Synthetic peptides containing
predicted immunogenic epitope(s) are the most widely used way
to create immunogens derived from virus antigens. However,
synthetic peptides are commonly linear and therefore often do
not represent the native features of antigens that originate from
the actual spatial structures of viral components.
On the other hand, cell-based protein expression systems
such as Escherichia coli or baculovirus-insect cell systems are
also widely used and popular approaches. Although a number
of cellular proteins have been successfully generated using a
cell-based approach, it is not feasible to use these strategies to
generate viral proteins, because many viral antigens including
FIGURE 5 | Determination of optimal pairs of mAbs for antigen-capture ELISA. (A) Schematic representation of sandwich ELISA. Each mAb was labeled with
horseradish peroxidase (HRP) and subjected to ELISA analysis. 49 pairs of antibodies were tested. (B) Determination of the optimal combination of capturing and
detection mAbs. S/N ratios for antigen detection by each of the 49 combinations were calculated in the presence of 0.1 ng/0.1 mL antigen V.S. blank. S/N values of
selected five pairs were depicted on each bar.
Frontiers in Microbiology | www.frontiersin.org 8 April 2016 | Volume 7 | Article 509
fmicb-07-00509 April 18, 2016 Time: 14:12 # 9
Yamaoka et al. Development of a Diagnostic Test for MERS-CoV
FIGURE 6 | Determination of optimal pairs of mAbs for ICT. (A) Schematic diagram of rapid ICT. (B) Selection of appropriate pairs of mAbs for ICT. Color
intensity of test line and background level were evaluated with antigen protein at 12.5 ng/0.1 mL. (C) Typical positive and negative results of ICT using the optimal
antibody pair (#20 and #46).
human coronavirus N proteins are generally insoluble and
aggregate in inclusion body fractions (Das and Suresh, 2006).
Moreover, viral proteins are often cytotoxic, and expression of
these proteins, particularly at high levels, can result in cell death
(Cheng et al., 2006). By contrast, the cell-free protein production
system permits synthesis of toxic proteins that otherwise cannot
be produced in live cells. Wheat germ extract, a commonly
used cell-free approach, utilizes a eukaryotic translation system
to synthesize properly folded and biologically active proteins
similar to those expressed in mammalian cells (Endo and
Sawasaki, 2005, 2006; Goshima et al., 2008). These advantages
highlight the suitability and availability of the wheat germ cell-
free system for the generation of antigenic proteins that can be
used to immunize animals and generate mAbs (Matsunaga et al.,
2014).
The results of this study clearly demonstrate the advantages
of using the wheat germ cell-free system for creating mAbs
against MERS-CoV-NP. In general, mAbs can be divided into
two groups, conformation-sensitive and -insensitive. Antibodies
can be suitable for immunoprecipitation, immunoblotting,
or both. A conformation-insensitive (immunoblotting-
oriented) mAb can detect denatured linear antigen or peptide
immobilized on membrane, whereas a conformation-sensitive
(immunoprecipitation-oriented) mAb typically recognizes
a native tertiary structure of antigen protein (Mancia et al.,
2007; Takeda et al., 2015). In this study, we used the wheat
germ system to synthesize MERS-NP antigen as a soluble
protein, and consequently we were able to produce antibodies
that specifically targeted antigenic epitopes located on the
surface of MERS-NP. Accordingly, our newly developed
antibodies were suitable for immunoprecipitation, indicating
that they are sensitive to protein conformation. Because
antibodies binding to protein surface epitopes are suitable
for antigen detection assays such as ELISA and ICT, our
newly create antibodies can be used in various immunological
assays.
Other than MERS-CoV, many types of human coronaviruses
are related to respiratory diseases. These include coronaviruses
such as HCoV-229E, -OC43, -NL63, and -HKU1, which
are responsible for common cold and upper respiratory
diseases, as well as SARS-CoV, which causes life-threatening
pneumonia. Therefore, it is important to create mAbs with
high specificity for MERS-CoV in order to rule out other
coronavirus infections. Previous reports indicated that the
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FIGURE 7 | No evidence of cross-reactivity with mAbs of other human coronaviruses. (A) Multiple sequence alignments of human coronavirus N proteins.
Shaded positions represent conserved residues among the sequences. Dashes indicate gaps in the aligned sequences. (B) Specificity of selected mAbs. His-tagged
NPs derived from several human coronaviruses were produced in the wheat germ extract system. Reactivity of generated mAbs was validated by immunoblot
analysis using either anti-His or the indicated antibodies.
NTD of NP of many human coronaviruses share common
sequences (Yu et al., 2005; Chang et al., 2014). Therefore,
we used a recombinant MERS-CoV-NP devoid of conserved
regions as an immunogen to produce mAbs. Consequently, our
newly developed mAbs can recognize species-specific amino-
acid sequences in MERS-CoV. Consistent with this, the mAbs
did not cross-react with NPs derived from other human
coronaviruses. Viral species can be determined by structural
characterization of the capsid/nucleocapsid (Gelderblom, 1996).
Therefore, we suspect that highly species-specific mAbs were
obtained due to the appropriate design and native properties of
the antigen.
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FIGURE 8 | Comprehensive detection of MERS-CoV isolates by the generated mAbs. (A) Distribution of amino-acid variation of NP in 113 MERS-CoV
strains. Shannon entropy, as a quantitative measure of variation, was calculated for each amino-acid residue of MERS-NP. Arrow indicates amino-acid mutation in
the epitope of mAb (#20) from two MERS-CoV strains. (B) Phylogenetic analysis of MERS-CoV based on multiple sequence alignment of NP. The unrooted
phylogeny is generated from amino-acid sequence alignments of nucleocapsid proteins based on the maximum-likelihood method. Sequences with identity of 100%
are removed from the dataset. Bootstrap values (1,000 replicates) are indicated around the branches. The scale bar represents amino-acid substitutions per site.
(C) Identification of amino-acid substitution in the antigenic epitope in 15 identical strains. Dots indicate sequence identity relative to the prototype strain. The R395H
substitution was noted in two strains. (D) Reactivity of mAb (#20) to MERS-NP (122–413) derived from the prototype and a mutant strain harboring R395H.
Reactivity was determined by immunoblot analysis.
Development of international trade and worldwide travel
brings about significant risk of the spread of emerging infectious
diseases, including MERS-CoV. Needless to say, there is no
obvious boundary between virus-free countries and those
facing endemics. Thus, the establishment of rapid and reliable
laboratory diagnostic tests for these pathogens is an urgent matter
in all countries. The most widely used current diagnostics for
MERS-CoV involve detection of virus nucleic acids by qRT-
PCR in the laboratory (Corman et al., 2012a,b). Although qRT-
PCR is a sensitive and powerful tool for obtaining evidence
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FIGURE 9 | Establishment of antigen detection assays for MERS-CoV. (A) Immunoblot analysis for virus particles of MERS-CoV. Cell culture medium of
MERS-CoV-infected Vero-TMPRSS2 cells were collected and analyzed by immunoblotting with the newly developed anti-MERS-NP mAbs. (B,C) Detection limit of
ELISA and ICT. Recombinant antigen protein and MERS-CoV were subjected to either ELISA or ICT analysis. + and − indicate positive and negative detection,
respectively; ± means moderately positive. Arrowheads show positive test line.
of virus infection, it requires specialized lab equipment and
expertise with molecular technology; moreover, due to the time
required for the enzymatic reaction, it is rather time-consuming.
These disadvantages prevent qRT-PCR from being used in
POCT. Therefore, case-oriented comprehensive tests should be
conducted using multiple diagnostic assays.
Enzyme-linked immunosorbent assay and ICT are two major
clinical tests used to detect viral antigens. Both methods employ
pairs of mAbs used as capture and detection antibodies. The
optimal combination of capture and detection antibodies should
be thoroughly investigated before the test kits are assembled.
In this study, the utilization of natively folded antigen protein
to evaluate each test allowed us to identify the optimal pair of
antibodies for the detection of MERS-CoV-NP. Our antibody set
is suitable for detecting MERS-CoV-NP by either ELISA or ICT.
At the early stage of illness, high titers of infectious virions
and virus antigens are present in the lower respiratory tract (LRT)
and sputum of patients. The viral loads in LRT and expectorated
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sputum of patients during acute infection are more than 106
copies/mL (Drosten et al., 2013; Kapoor et al., 2013; Corman
et al., 2015), making it feasible to detect viral antigens of MERS-
CoV for clinical diagnosis at an early stage of infection. The
current version of our assay can detect 0.0625 (ELISA) or 0.5 ng
(ICT) of recombinant N protein and 1.5 × 105 (ELISA) or
3.0 × 106 viral copies (ICT), ensuring its feasibility in practical
clinical tests.
Other groups have also developed antigen-capture ELISA
and ICT for detection of MERS-NP antigen (Chen et al.,
2015; Song et al., 2015). Song et al. used synthetic peptides
as immunogens to raise an NP-specific mAb. The other group
used recombinant N proteins as antigens, but did not perform
precise epitope mapping (Chen et al., 2015). On the other hand,
we developed structure-sensitive mAbs against MERS-NP and
thoroughly investigated their targeting epitopes. Bioinformatic
analysis based on a phylogenetic approach further revealed that
our newly developed mAbs can detect NP antigens derived from
existing isolates of MERS-CoV.
In summary, we developed a novel antigen-detection assay
using newly created mAbs for the rapid and reliable assessment
of NP antigen of MERS-CoV. Further evaluations using actual
patient samples warrants the usability and benefit of this assay
for the clinical diagnosis of MERS-CoV infection.
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